Does empagliflozin reduce adverse heart failure and renal outcomes in patients with chronic heart failure with reduced ejection fraction regardless of MRA use?
Empagliflozin maintains its efficacy in HFrEF regardless of background MRA use and may facilitate the continuation of MRA therapy.
In EMPEROR-Reduced, the use of MRAs did not influence the effect of empagliflozin to reduce adverse heart failure and renal outcomes. Treatment with empagliflozin was associated with less discontinuation of MRAs. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction EMPEROR-Reduced; NCT03057977).
“For patients with HFrEF in 2021, the central therapeutic goal is for eligible patients to receive target or maximally tolerated doses of a four-member team of medications. If we can harness SGLT2 inhibitors to help [guideline-directed medical therapy] teammates get on the field and stay in the ga...”
Ferreira et al. (Mon,) studied this question.